Stevens E, Kochuyt A M
Allergy. 1984 Apr;39(3):179-82. doi: 10.1111/j.1398-9995.1984.tb02622.x.
Sodium cromoglycate formulated as a pressurised aerosol was compared with the conventional powder for a period of 12 weeks in a double-blind group comparison trial involving 48 patients. A double dummy technique was used; the dose of sodium cromoglycate was 2 mg four times daily by aerosol, and 20 mg four times daily by Spinhaler. Patients were able to use the correct technique for both aerosol and dry powder inhalation. Patients recorded the severity of their asthma symptoms, their morning and evening peak flow rate, and the amount of other asthma therapy used, on a daily diary card. They also attended the clinic every 4 weeks for assessment. A statistical comparison of the efficacy of the powder and aerosol forms found no significant differences in clinical assessment of severity, diary card symptom scores, morning and evening peak flow readings, or aerosol bronchodilator usage. Thirty-four patients considered that the aerosol was more convenient and easier to use than the dry powder inhaler.
在一项涉及48名患者的双盲组对比试验中，将制成加压气雾剂的色甘酸钠与传统粉末进行了为期12周的比较。采用了双模拟技术；色甘酸钠的剂量为气雾剂每日4次，每次2毫克，Spinhaler干粉吸入器每日4次，每次20毫克。患者能够正确使用气雾剂和干粉吸入技术。患者在每日记录卡上记录哮喘症状的严重程度、早晚峰值流速以及使用的其他哮喘治疗药物的量。他们还每4周到诊所进行评估。对粉末和气雾剂形式的疗效进行统计比较发现，在严重程度的临床评估、记录卡症状评分、早晚峰值流速读数或气雾剂支气管扩张剂使用方面没有显著差异。34名患者认为气雾剂比干粉吸入器更方便、更容易使用。
